National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.50
add to cart

Rights & Permissions

topleft topright

New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries (1986)
Board on Population Health and Public Health Practice (BPH)

Citation Manager

. "Appendix I: Contents of Supplement to Volume II." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.

Please select a format:

BibTeX EndNote RefMan


Page
420
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries

Appendix I
Contents of Supplement to Volume II

I.1

The Prospects for Immunizing Against Brucella abortus

I.2

The Prospects for Immunizing Against Campylobacter

I.3

The Prospects for Immunizing Against Chlamydia spp.

I.4

The Prospects for Immunizing Against Entamoeba histolytica

I.5

The Prospects for Immunizing Against Filaria spp.

I.6

The Prospects for Immunizing Against Giardia lamblia

I.7

The Prospects for Immunizing Against Hantaan Virus

I.8

The Prospects for Immunizing Against Leishmania spp.

I.9

The Prospects for Immunizing Against Measles Virus

I.10

The Prospects for Immunizing Against Measles Virus

I.11

The Prospects for Immunizing Against Mycobacterium tuberculosis

I.12

The Prospects for Immunizing Against Nematodes

I.13

The Prospects for Immunizing Against Qnchocerca volvulus

I.14

The Prospects for Immunizing Against Salmonella Non-Typhi

I.15

The Prospects for Immunizing Against Schistosoma spp.

I.16

The Prospects for Immunizing Against Streptococcus Group B

I.17

The Prospects for Immunizing Against African Trypanosoma spp.

I.18

The Prospects for Immunizing Against South American Trypanosoma spp.

J

New Approaches to Vaccine Development

To be available on a “publication on demand” basis from the National Academy Press.

Page
420
Front Matter (R1-R16)
1. Summary (1-18)
2. Priority Setting for Health-Related Investments: A Review of Methods (19-29)
3. Overview of the Analytic Approach (30-43)
4. Comparison of Disease Burdens (44-62)
5. Predictions of Vaccine Development (63-75)
6. Assessing the Likely Utilization of New Vaccines (76-81)
7. Calculation and Comparison of the Health Benefits and Differential Costs Associated with Candidate Vaccines (82-105)
8. Additional Issues in the Selection of Priorities for Accelerated Vaccine Development (106-120)
9. Findings, Conclusions, and Recommendations (121-142)
Appendix A: Selection of Vaccine Candidates for Accelerated Development (143-148)
Appendix B: The Burden of Disease Resulting from Acute Respiratory Illness (149-158)
Appendix C: The Burden of Disease Resulting from Diarrhea (159-169)
Appendix D-1: The Prospects for Immunizing Against Dengue Virus (170-177)
Appendix D-2: The Prospects for Immunizing Against Escherichia coli (178-185)
Appendix D-3: The Prospects for Immunizing Against Hemophilus influenzae Type b (186-196)
Appendix D-4: The Prospects for Immunizing Against Hepatitis A Virus (197-207)
Appendix D-5: The Prospects for Immunizing Against Hepatitis B Virus (208-222)
Appendix D-6: The Prospects for Immunizing Against Japanese Encephalitis Virus (223-240)
Appendix D-7: The Prospects for Immunizing Against Mycobacterium leprae (241-250)
Appendix D-8: The Prospects for Immunizing Against Neisseria meningitidis (251-266)
Appendix D-9: The Prospects for Immunizing Against Parainfluenza Viruses (267-274)
Appendix D-10: The Prospects for Immunizing Against Plasmodium spp. (275-286)
Appendix D-11: The Prospects for Immunizing Against Rabies Virus (287-298)
Appendix D-12: The Prospects for Immunizing Against Respiratory Syncytial Virus (299-307)
Appendix D-13: The Prospects for Immunizing Against Rotavirus (308-318)
Appendix D-14: The Prospects for Immunizing Against Salmonella typhi (319-328)
Appendix D-15: The Prospects for Immunizing Against Shigella spp. (329-337)
Appendix D-16: The Prospects for Immunizing Against Streptococcus Group A (338-356)
Appendix D-17: The Prospects for Immunizing Against Streptococcus pneumoniae (357-375)
Appendix D-18: The Prospects for Immunizing Against Vibrio cholerae (376-389)
Appendix D-19: The Prospects for Immunizing Against Yellow Fever (390-402)
Appendix E: Questionnaire for Assessing Morbidity-Mortality Trade-Offs (403-411)
Appendix F: Technical Notes (412-412)
Appendix G: Biographical Notes on Committee Members (413-417)
Appendix H: Additional Sources of Advice to the Committee (418-419)
Appendix I: Contents of Supplement to Volume II (420-420)
Appendix J: Preface to Volume I (421-422)
Appendix K: Contents to Volume I (423-423)
Index (424-432)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 420
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries Appendix I Contents of Supplement to Volume II I.1 The Prospects for Immunizing Against Brucella abortus I.2 The Prospects for Immunizing Against Campylobacter I.3 The Prospects for Immunizing Against Chlamydia spp. I.4 The Prospects for Immunizing Against Entamoeba histolytica I.5 The Prospects for Immunizing Against Filaria spp. I.6 The Prospects for Immunizing Against Giardia lamblia I.7 The Prospects for Immunizing Against Hantaan Virus I.8 The Prospects for Immunizing Against Leishmania spp. I.9 The Prospects for Immunizing Against Measles Virus I.10 The Prospects for Immunizing Against Measles Virus I.11 The Prospects for Immunizing Against Mycobacterium tuberculosis I.12 The Prospects for Immunizing Against Nematodes I.13 The Prospects for Immunizing Against Qnchocerca volvulus I.14 The Prospects for Immunizing Against Salmonella Non-Typhi I.15 The Prospects for Immunizing Against Schistosoma spp. I.16 The Prospects for Immunizing Against Streptococcus Group B I.17 The Prospects for Immunizing Against African Trypanosoma spp. I.18 The Prospects for Immunizing Against South American Trypanosoma spp. J New Approaches to Vaccine Development To be available on a “publication on demand” basis from the National Academy Press.

Representative terms from entire chapter:

histolytica filaria